CytoDyn Inc. (CYDY) Form 8-K — Nov 17, 2026
$CYDYForm 8-KItems 5.02, 7.01, 9.01Filed Nov 17, 2026, 4:33 PM ET0001175680-26-000042Original filing
CytoDyn announced on November 17, 2026 the appointment of Lauren Wilcoxen, Ph.D. as Chief Operating Officer and Head of Regulatory Affairs, effective November 20, 2026. Dr. Wilcoxen most recently served as SVP of Regulatory Affairs at Xilio Therapeutics and previously helped secure FDA approval of a checkpoint inhibitor at Checkpoint Therapeutics before its acquisition by Sun Pharmaceutical.
Key figures
- Base Salary
- 425000
- Fiscal Year End
- May 31, 2027
- Option Vesting
- 4-year vesting
- Target Annual Bonus
- 40% of base salary
- Stock Options Granted
- 4500000
AI analysis
Red flags2 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.